The importance of circulating tumor cells and tumor models in future of cancer therapy
The importance of circulating tumor cells and tumor models in future of cancer therapy
Development of new technologies is taking cancer research on a new journey in which plenty of mysterious aspects of cancer biology are being unraveled. To defeat cancer, we first need to understand the biology of this smart complex system, which often hijacks several programs to proliferate, invade, escape the immune system and colonize distant organs. Therefore, studying cancer cells in every step of tumor development (including primary tumor formation, invasion, circulation and metastatic colonization) is absolutely essential. Analysis of human-derived cancer models in primary site, circulation or metastatic lesions outside their host is one of the most promising ways to understand these complexities. The most common currently used and more recently developed cancer cell lines consist of primary patient-derived tumor xenograft (PDTX), circulating tumor cells isolation and analyzes, and primary tumor organoids. In this chapter we provide a brief update of some of the most important advances in studying and treatment of cancer using new technologies
article, cancer growth, cancer research, cancer resistance, cancer therapy, circulating tumor cell, human, immune deficiency, microfluidic analysis, nonhuman, protein expression, tumor escape, tumor microenvironment, tumor model, tumor xenograft
121-135
Behnam, B.
bb3a7da7-42d7-40c0-ac86-18bdecb71732
Fazilaty, H.
d9c7bf1b-abd3-44cb-9e78-2984037ea9d9
Roghanian, A.
e2b032c2-60a0-4522-a3d8-56a768792f36
2017
Behnam, B.
bb3a7da7-42d7-40c0-ac86-18bdecb71732
Fazilaty, H.
d9c7bf1b-abd3-44cb-9e78-2984037ea9d9
Roghanian, A.
e2b032c2-60a0-4522-a3d8-56a768792f36
Behnam, B., Fazilaty, H. and Roghanian, A.
(2017)
The importance of circulating tumor cells and tumor models in future of cancer therapy.
In,
Aref, A. and Barbie, D.
(eds.)
Ex Vivo Engineering of the Tumor Microenvironment.
(Cancer Drug Discovery and Development (CDD&D))
Cham.
Humana, .
(doi:10.1007/978-3-319-45397-2_7).
Record type:
Book Section
Abstract
Development of new technologies is taking cancer research on a new journey in which plenty of mysterious aspects of cancer biology are being unraveled. To defeat cancer, we first need to understand the biology of this smart complex system, which often hijacks several programs to proliferate, invade, escape the immune system and colonize distant organs. Therefore, studying cancer cells in every step of tumor development (including primary tumor formation, invasion, circulation and metastatic colonization) is absolutely essential. Analysis of human-derived cancer models in primary site, circulation or metastatic lesions outside their host is one of the most promising ways to understand these complexities. The most common currently used and more recently developed cancer cell lines consist of primary patient-derived tumor xenograft (PDTX), circulating tumor cells isolation and analyzes, and primary tumor organoids. In this chapter we provide a brief update of some of the most important advances in studying and treatment of cancer using new technologies
This record has no associated files available for download.
More information
e-pub ahead of print date: 10 December 2016
Published date: 2017
Keywords:
article, cancer growth, cancer research, cancer resistance, cancer therapy, circulating tumor cell, human, immune deficiency, microfluidic analysis, nonhuman, protein expression, tumor escape, tumor microenvironment, tumor model, tumor xenograft
Identifiers
Local EPrints ID: 413399
URI: http://eprints.soton.ac.uk/id/eprint/413399
ISSN: 2196-9914
PURE UUID: 7f1a88fc-f9fc-49de-97cc-79f5bcc34951
Catalogue record
Date deposited: 23 Aug 2017 16:32
Last modified: 16 Mar 2024 04:01
Export record
Altmetrics
Contributors
Author:
B. Behnam
Author:
H. Fazilaty
Editor:
A. Aref
Editor:
D. Barbie
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
